Servier

The largest independent French pharmaceutical group, Servier has operated without stock-market listing since its founding in 1954, a deliberate structure that channels the entirety of its profits back into research and development rather than shareholder returns. Headquartered in Suresnes, France, the group employs more than 22,000 people across over 150 countries, making it one of the most globally distributed privately held pharma companies in the world.

Oncology as the Strategic Priority

Servier formally repositioned oncology as its lead therapeutic focus following the acquisition of Agios Pharmaceuticals' oncology business in 2021, a transaction that brought the approved medicines Tibsovo (ivosidenib) and Vorasidenib into its portfolio alongside a clinical pipeline targeting IDH-mutant cancers. The group's oncology efforts concentrate on haematology and solid tumours, with IDH inhibition representing a scientifically distinctive area where Servier holds meaningful intellectual depth.

Cardiovascular Heritage & Broader Therapeutic Scope

Beyond oncology, Servier carries a long-established heritage in cardiovascular medicine, an area in which the group built its original scientific reputation over several decades. The portfolio also spans neuroscience, diabetes and metabolism, and immuno-inflammatory diseases. Servier's branded generics division, Biogaran, operates as a major generics supplier within France and select European markets, extending the group's commercial reach across price-sensitive segments.

Research investment consistently represents roughly 20 percent of annual turnover, a commitment reinforced by the group's independent ownership model. Servier operates its own manufacturing network across Europe and maintains a significant presence in emerging markets, particularly across Africa, where long-standing commercial relationships give it an unusually broad footprint for a company of its ownership structure.

The group's Institut de Recherches Servier coordinates preclinical and clinical research globally, with sites in France, the United Kingdom, Hungary, and beyond. Servier is a signatory to the Innovative Medicines Initiative and participates in public-private partnerships across European research consortia.

Further information is available at servier.com.